ClinicalTrials.gg
CompletedNCT05434286Updated Nov 13, 2026

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury

An observational study in Hepatorenal Syndrome, Cirrhosis, Liver and Acute-On-Chronic Liver Failure, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Completed at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Observational

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately.

We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) \& cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).

02

Conditions studied

  • Hepatorenal Syndrome
  • Cirrhosis, Liver
  • Acute-On-Chronic Liver Failure
  • AKI
  • Refractory Ascites
03

In context

Hepatorenal Syndrome

50 studies on the registry are indexed under Hepatorenal Syndrome; 7 are open to participants now.

This study's enrollment of 140 is close to the median of 140 across 11 observational studies indexed under Hepatorenal Syndrome.

Browse Hepatorenal Syndrome studies →

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cirrhosis of any etiology, aged between 18-65 years, with hepatorenal syndrome (HRS-AKI).

Acute kidney injury (AKI) (increase in serum creatinine by 0.3 mg/dL in less than 48 hour or an increase in serum creatinine by 50% from a stable baseline reading within 3 months) has been proposed to characterize renal dysfunction in patients with cirrhosis, in which type 1 HRS would be reclassified as HRS-AKI.

Stage 1 AKI would be classified as an increase in serum creatinine level by 0.3 mg/dL or a 50% increase, whereas stages 2 and 3 AKI would be a doubling and tripling, respectively, of serum creatinine levels.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cirrhosis of any Etiology
  • Patient with acute kidney injury meeting HRS-AKI criteria

Exclusion criteria

Exclusion Criteria:

  • Hepatocellular carcinoma
  • Patients with active variceal bleeding
  • or severe state
  • Chronic kidney disease (CKD) on renal replacement therapy (RRT),
  • Previous transjugular intra hepatic portosystemic shunt (TIPS)
  • Porto-pulmonary hypertension,
  • Coronary artery disease
  • Congenital or valvular heart disease
  • Prosthetic cardiac valves
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cirrhosis/ACLF of any etiology

    Cirrhosis with hepatorenal syndrome-acute kidney injury (HRS-AKI) as per International Ascites Club criteria.

    Diagnostic Test: Echocardiographic assessment

Interventions

  • Diagnostic testEchocardiographic assessment

    POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin

06

What researchers measure

Primary outcomes

  1. Cardiac output measurement by echocardiography

    Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0 and 48 hours after enrollment. The cardiac output at 7 days after enrollment will also be documented. he Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000

    Time frame: Day 0, Day 2, Day 7.

  2. IVC size and collapsibility changes

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 0.

  3. IVC size and collapsibility changes

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 2

  4. IVC size and collapsibility changes

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 7.

  5. Number of patients with Complete Response in HRS-AKI

    Complete response is defined as a reversal in AKI with a final serum Creatinine (sCr) value of ≤ 0.3 mg/dL of the baseline.

    Time frame: Day 7

  6. Number of patients with Partial Response in HRS-AKI

    Partial response is defined as regression in the stage of AKI with a final sCr \> 0.3 mg/dL above the baseline.

    Time frame: Day 7

  7. Number of patients with Non-Response in HRS-AKI

    Non-responder is defined if the sCr did not decrease or increased from the baseline.

    Time frame: Day 7

Secondary outcomes

  1. Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level

    Time frame: Day 0 and Day 7

  2. Change in NT Pro brain natriuretic peptide (BNP) level

    Time frame: Day 0 and Day 7

  3. Change in plasma renin activity level

    Time frame: Day 0 and Day 7

  4. Change in Galectin-3 level

    Time frame: Day 0 and Day 7

07

Study locations

1 site
  • PGIMER
    Chandigarh, National Capital Territory of Delhi 160012, India
08

References and documents

Publications

  • Adebayo D, Neong SF, Wong F. Refractory Ascites in Liver Cirrhosis. Am J Gastroenterol. 2019 Jan;114(1):40-47. doi: 10.1038/s41395-018-0185-6. PubMed 29973706 ↗
  • Premkumar M, Kajal K, Reddy KR, Izzy M, Kulkarni AV, Duseja AK, Sihag KB, Divyaveer S, Gupta A, Taneja S, De A, Verma N, Rathi S, Bhujade H, Chaluvashetty SB, Roy A, Kumar V, Siddhartha V, Singh V, Bahl A. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology. 2024 May 1;79(5):1048-1064. doi: 10.1097/HEP.0000000000000691. Epub 2023 Nov 16. PubMed 37976391 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Mar 2025, 39 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2023 → Mar 2025 and completion Jun 2023 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 28, 2022
StartActual
Dec 15, 2021
Primary completionActual
Mar 15, 2025was Mar 2023
CompletionActual
Jun 15, 2026was Jun 2023
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • PGIMER · Chandigarh, India
Show 1 removed
  • PGIMER · Chandigarh, India
Nov 13, 2026
Primary completion
Mar 15, 2023→Mar 15, 2025
Nov 13, 2026
Study completion
Jun 15, 2023→Jun 15, 2026 (actual)
Nov 13, 2026
Enrollment
75 (estimated)→140 (actual)
Nov 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37976391 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37976391 ↗
    1 site added, 1 site removed
    Show site
    • PGIMER · Chandigarh, India
    Show 1 removed
    • PGIMER · Chandigarh, India
    Primary completion Mar 15, 2023→Mar 15, 2025
    Study completion Jun 15, 2023→Jun 15, 2026 (now actual)
    Enrollment 75 (estimated)→140 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05434286
Responsible party
Madhumita Premkumar (Associate Professor, Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Jun 28, 2022
Start date
Dec 15, 2021
Primary completion
Mar 15, 2025
Completion
Jun 15, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion